Cost-effectiveness of cabotegravir long-acting for pre-exposure prophylaxis versus current use of daily oral tenofovir disoproxil fumarate/emtricitabine or no prep to prevent HIV-1 in individuals at high risk in Spain.

Ashley Davis Smith; Kelly Campbell; V Neches; Kelly Campbell; P Coll; S Moreno Guillen; JM  Martinez-Sesmero; F Lopez Segui; P O'Brien; Ashley E. Davis; SJ Anderson; M Schroeder; LA Vallejo-Aparicio

Cost-effectiveness of cabotegravir long-acting for pre-exposure prophylaxis versus current use of daily oral tenofovir disoproxil fumarate/emtricitabine or no prep to prevent HIV-1 in individuals at high risk in Spain.

Neches, V., Campbell, K., Coll, P., Moreno Guillen, S., Martinez-Sesmero, JM., Lopez Segui, F., O'Brien, P., Davis, A. E., Anderson, SJ., Schroeder , M., & Vallejo-Aparicio, LA. (2024). Cost-effectiveness of cabotegravir long-acting for pre-exposure prophylaxis versus current use of daily oral tenofovir disoproxil fumarate/emtricitabine or no prep to prevent HIV-1 in individuals at high risk in Spain. Value in Health, 27(6).

Copy citation